Posts with tag StockWatch
StockWatch: Between the Bells with Timothy Sykes
Continue reading StockWatch: Between the Bells with Timothy Sykes
StockWatch: Between the Bells with Kevin Depew
Continue reading StockWatch: Between the Bells with Kevin Depew
StockWatch: Between the Bells with Peter Cohan
Continue reading StockWatch: Between the Bells with Peter Cohan
StockWatch: Between the Bells with Georges Yared
Not so fast, you folks crying bear! In the latest edition of StockWatch: Between The Bells, BloggingStocks' own Georges Yared says this is still a bull market, although it's undergone significant correction. The chief investment strategist of Yared Investment Research says this is a market of much opportunity.
Continue reading StockWatch: Between the Bells with Georges Yared
StockWatch: Between the Bells with Timothy Sykes
Continue reading StockWatch: Between the Bells with Timothy Sykes
StockWatch: Between the Bells with Doug McIntyre
Continue reading StockWatch: Between the Bells with Doug McIntyre
StockWatch: Between the Bells with Todd Harrison
Continue reading StockWatch: Between the Bells with Todd Harrison
StockWatch: Between the Bells with Ken Kam
Agreeing with recent StockWatch contributors, Ken says now is the time to be bullish. The ongoing mortgage meltdown may have spooked the credit markets, but companies themselves are doing well. Ken sees choice buying opportunities available for investors who have done their research.
Alas, Ken says it's still too early to return to the housing sector, despite discounted shares throughout the sector. The Federal Reserve's rate cut last month may have eased the worries of securitized mortgage owners, but the immediate future looks gray for homebuilders.
Instead, Ken recommends hunting for opportunity in the energy sector. Pausing recently after three years of growth, the energy sector now looks primed to gush again, if oil's unprecedented highs are any indicator.
Just looking for a hot tip? Ken's got one for you: Elan (NYSE: ELN). With buyout buzz surrounding its partner Biogen Idec (NASDAQ: BIIB), Elan could soon make a play for full rights to their joint multiple sclerosis drug, Tysabri.
Want more tips? Check out these recent StockWatch interviews:
- Midas Funds portfolio manager Thomas Winmill
- Timothy Sykes, author of An American Hedge Fund: How I Made $2 Million as a Stock Operator & Created a Hedge Fund
- AOL Money Coach Hilary Kramer
StockWatch: Between the Bells with Timothy Sykes
Tim has three daring tips for you. Digital content storage provider Isilon Systems (NASDAQ: ISLN) is sitting at an all-time low, more than 70% off its high at the start of the year, and looks priced to buy. Genetics biotech Illumina Inc. (NASDAQ: ILMN) is currently trading around $52; Tim sees ILMN climbing to $60. Sound a little too risky? Tim suggests checking out The Bruce Fund (BRUFX), a mutual fund focusing on domestic common stock, convertible bonds and zero-coupon government bonds.
Considering a short-selling strategy? Tim calls out China Precision Steel (NASDAQ: CPSL), which has jumped more than three-fold in little more than a week and looks set to slide.
Jamba Juice (NASDAQ: JMBA), meanwhile, is giving Tim fits -- revenues are up while same-store sales are slipping. He advises to stay away from JMBA.
Enjoy the clip, and let us know which of your favorite stock gurus you'd like to hear from in the next StockWatch: Between the Bells!









